Results 131 to 140 of about 273,783 (254)
ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna +16 more
wiley +1 more source
Combining legal epidemiology and implementation science to improve global access to medicines: challenges and opportunities. [PDF]
Lane J, Stergachis A.
europepmc +1 more source
ABSTRACT Background Person‐centred follow‐up care based on evidence‐based clinical practice guidelines and providing individualised information should help to inform and reassure survivors about their medical and psychosocial situation and provide treatment and support where needed.
Gisela Michel +36 more
wiley +1 more source
Governing access to medicines in Central America: community pharmacy, patient safety, and lessons from Spain. [PDF]
Zavaleta-Monestel E +3 more
europepmc +1 more source
ABSTRACT Background Secretory phospholipase A2 (sPLA2) is an inflammatory mediator linked to acute chest syndrome (ACS) in sickle cell disease (SCD), a serious complication that can develop during an acute vaso‐occlusive pain episode (VOE). Plasma sPLA2 levels have been proposed as a potential biomarker for predicting ACS onset.
Rawan Korman +10 more
wiley +1 more source
From Legislative Harmonization to Real-World Access: A Scoping Review of Pharmaceutical Regulation and Access to Medicines in Romania. [PDF]
Negrila CD +3 more
europepmc +1 more source
ABSTRACT Background Japan's 2024 physician work‐style reform introduced legally binding limits on physicians’ working hours, but its impact on education and workforce sustainability in pediatric hematology–oncology (PHO) remains unclear. Procedure We conducted a repeated cross‐sectional study with structured quantitative items and free‐text responses ...
Kiyohiko Kaizu +7 more
wiley +1 more source
Access to medicines for rare diseases: A European regulatory roadmap for academia. [PDF]
Rosenberg N +7 more
europepmc +1 more source
A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024
ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho +7 more
wiley +1 more source
Inequitable access to medicines for neglected tropical diseases in Europe: health system vulnerabilities and a call for coordinated action. [PDF]
Ravinetto R +9 more
europepmc +1 more source

